Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Research from A. Dey et al broadens understanding of cancer
February 5th, 2009
According to recent research published in the journal Cell Cycle, "Hexamethylene Bisacetamide (HMBA) is a hybrid polar compound originally developed as a differentiation inducing agent. We show in this study that HMBA can inhibit activation of several NF kappa B target genes in both lung and breast cancer cell lines." "Furthermore, consistent with its ability to inhibit NF kappa B function, HMBA can also sensitize cells to apoptosis. We show that HMBA mediates inhibition of the Akt and ERK/MAPK cascade, both of which are critical for cell survival and proliferation and are well known regulators of NF kappa B activation. We also show that PTEN negative breast...
Source: Women's Health Weekly (2009-02-05)
|
